MedTrace Logo

Open Label Clinical Trial of Intravenous Crotoxin Part 3

NCT01481532 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-04-15

No results posted yet for this study

Summary

The primary objective of the study is to assess whether human subjects can be made tolerant to intravenously administered Crotoxin and achieve higher and more therapeutically effective doses levels without the previously reported adverse effects associated with bolus i.m. administration.

Conditions

Interventions

DRUG

Crotoxin

Intra patient dose escalation

Sponsors & Collaborators

  • Institut de Cancérologie de l'Ouest

    collaborator UNKNOWN

  • Celtic Biotech Ltd

    lead INDUSTRY

Principal Investigators

  • Mario Campone, MD, Ph.D · INSTITUT DE CANCEROLOGIE DE L'QUEST, Saint Herblain, France

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-31
Primary Completion
2027-10-31
Completion
2027-11-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01481532 on ClinicalTrials.gov